Skip to main content
SpringerLink
Log in

Toxicity and Efficacy of Treating Mediastinal and Hilar Lesions

  • Chapter
Treating Tumors that Move with Respiration

Abstract

When pondering the choice of therapy for a cancer, clinicians must weigh the risks and benefits of each modality individually for each patient, taking into account age, coexisting medical problems, general fitness, therapeutic toxicity, and therapeutic efficacy. This chapter will focus on lung cancer and other tumors in an area of the chest fraught with potential complications: the mediastinum and hilum. We will briefly review the literature on toxicity and efficacy of radiotherapy to the central chest, and then present some of our early experience with stereotactic body radiotherapy (SBRT) to this difficult area.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med 1977;86:81–92.

    PubMed  CAS  Google Scholar 

  2. Rubin P, Siemann DW, Shapiro DL, et al. Surfactant release as an early measure of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1983;9:1669–1673.

    PubMed  CAS  Google Scholar 

  3. Monson JM, Stark P, Reilly JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 1998;82:842–850.

    Article  PubMed  CAS  Google Scholar 

  4. McDonald S, Rubin P, Phillips TL, et al. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995;31:1187–1203.

    Article  PubMed  CAS  Google Scholar 

  5. Thomas C. Thoracic Tumors: Overview. In: Gunderson LL, Tepper JE, editors. Clinical Radiation Oncology. London: Churchill Livingston; 2000. p. 580.

    Google Scholar 

  6. Polansky SM, Ravin CE, Prosnitz LR. Pulmonary changes after primary irradiationfor early breast carcinoma. AJR Am J Roentgenol 1980;134:101–105.

    PubMed  CAS  Google Scholar 

  7. Shapiro SJ, Shapiro SD, Mill WB, et al. Prospective study of long-term pulmonary manifestations of mantle irradiation. Int J Radiat Oncol Biol Phys 1990;19:707–714.

    PubMed  CAS  Google Scholar 

  8. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109–122.

    PubMed  CAS  Google Scholar 

  9. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323–329.

    Article  PubMed  CAS  Google Scholar 

  10. Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 2006;65:1075–1086.

    Article  PubMed  Google Scholar 

  11. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666–670.

    Article  PubMed  CAS  Google Scholar 

  12. Uematsu M. CT-guided stereotactic radiation therapy (SRT) for stage I NSCLC: 8 year results of 50 initial patients IJROBP; 57:S281. American Society for Therapeutic Radiation Oncology. Salt Lake City, Utah; 2003.

    Google Scholar 

  13. Hof H, Herfarth KK, Munter M, et al. Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2003;56:335–341.

    Article  PubMed  Google Scholar 

  14. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427–1431.

    Article  PubMed  Google Scholar 

  15. McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2005;63:1010–1015.

    Article  PubMed  Google Scholar 

  16. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006;45:787–795.

    Article  PubMed  Google Scholar 

  17. Le QT, Loo BW, Ho A, et al. Results of a phase I doseescalation study using single-fraction stereotactic radiotherapy for lung tumors. Journal of Thoracic Oncology 2006;1:802–809.

    PubMed  Google Scholar 

  18. Bradley J, Movsas B. Radiation esophagitis: Predictive factors and preventive strategies. Semin Radiat Oncol 2004;14:280–286.

    Article  PubMed  Google Scholar 

  19. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940–945.

    Article  PubMed  CAS  Google Scholar 

  20. Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358–364.

    Article  PubMed  CAS  Google Scholar 

  21. Werner-Wasik M. Treatment-related esophagitis. Semin Oncol 2005;32:S60–66.

    Article  PubMed  Google Scholar 

  22. Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys 1995;31:1213–1236.

    Article  PubMed  CAS  Google Scholar 

  23. Bradley J, Deasy JO, Bentzen S, et al. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 2004;58:1106–1113.

    PubMed  Google Scholar 

  24. Choy H, LaPorte K, Knill-Selby E, et al. Esophagitis in combined modality therapy for locally advanced nonsmall cell lung cancer. Semin Radiat Oncol 1999;9:90–96.

    PubMed  CAS  Google Scholar 

  25. Werner-Wasik M, Pequignot E, Leeper D, et al. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 2000;48:689–696.

    Article  PubMed  CAS  Google Scholar 

  26. Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998;16:3316–3322.

    PubMed  CAS  Google Scholar 

  27. Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003;55:337–341.

    Article  PubMed  Google Scholar 

  28. Curran W, Scott C, Langer C. Phase III comparisons of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410. 9th World Conference on Lung Cancer. Tokyo; 2000. p. 303.

    Google Scholar 

  29. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 2005;23:2145–2154.

    Article  PubMed  CAS  Google Scholar 

  30. Onimaru R, Shirato H, Shimizu S, et al. Tolerance of organs at risk in small-volume, hypofractionated, imageguided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 2003;56:126–135.

    Article  PubMed  Google Scholar 

  31. Wulf J, Hadinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001;177:645–655.

    Article  PubMed  CAS  Google Scholar 

  32. Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer-mature results for medically inoperable patients. Lung Cancer 2006;51:97–103.

    Article  PubMed  Google Scholar 

  33. Hayakawa K, Mitsuhashi N, Saito Y, et al. Short communication: adverse chronic effects of high-dose irradiation on proximal bronchus in patients treated for bronchogenic carcinoma. Br J Radiol 1993;66:477–479.

    Article  PubMed  CAS  Google Scholar 

  34. Miller KL, Shafman TD, Anscher MS, et al. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys 2005;61:64–69.

    Article  PubMed  Google Scholar 

  35. Speiser BL, Spratling L. Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation. Int J Radiat Oncol Biol Phys 1993;25:589–597.

    PubMed  CAS  Google Scholar 

  36. Hennequin C, Tredaniel J, Chevret S, et al. Predictive factors for late toxicity after endobronchial brachytherapy: a multivariate analysis. Int J Radiat Oncol Biol Phys 1998;42:21–27.

    Article  PubMed  CAS  Google Scholar 

  37. Uno T, Aruga T, Isobe K, et al. Radiation bronchitis in lung cancer patient treated with stereotactic radiation therapy. Radiat Med 2003;21:228–231.

    PubMed  Google Scholar 

  38. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101:1623–1631.

    Article  PubMed  Google Scholar 

  39. Song DY, Benedict SH, Cardinale RM, et al. Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probabilitybased dose limits. Am J Clin Oncol 2005;28:591–596.

    Article  PubMed  Google Scholar 

  40. Hara R, Itami J, Aruga T, et al. Risk factors for massive hemoptysis after endobronchial brachytherapy in patients with tracheobronchial malignancies. Cancer 2001;92:2623–2627.

    Article  PubMed  CAS  Google Scholar 

  41. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833–4839.

    Article  PubMed  Google Scholar 

  42. Cosset JM, Henry-Amar M, Girinski T, et al. Late toxicity of radiotherapy in Hodgkin’s disease. The role of fraction size. Acta Oncol 1988;27:123–129.

    PubMed  CAS  Google Scholar 

  43. Stewart JR, Fajardo LF, Gillette SM, et al. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995;31:1205–1211.

    Article  PubMed  CAS  Google Scholar 

  44. Takayama K, Nagata Y, Negoro Y, et al. Treatment planning of stereotactic radiotherapy for solitary lung tumor. Int J Radiat Oncol Biol Phys 2005;61:1565–1571.

    Article  PubMed  Google Scholar 

  45. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946–1955.

    Article  PubMed  Google Scholar 

  46. Timmerman RD, Story M. Stereotactic body radiation therapy: a treatment in need of basic biological research. Cancer J 2006;12:19–20.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, St. Joseph’s Hospital, Saint Paul, MN, 55102, USA

    Andrew S. Fink MD (Medical Director)

  2. Radiation Medicine, St. Joseph’s Hospital, Saint Paul, MN, 55102, USA

    June A. Kim MD (Medical Director)

  3. CyberKnife Center, St. Joseph’s Hospital, Saint Paul, MN, 55102, USA

    D. Ross McBride MD (Medical Director), Jodi L. Mammenga BA, Guy R. Sherwood DABR (Senior Medical Physicist) & Lori Copsey CMD, BS (Medical Physicist)

  4. Department of Family Medicine, University of Minnesota, Minneapolis, MN, 55455, USA

    Micheal J. Hervey II MD

  5. HealthEast Research and Education, Saint Paul, MN, 55102, USA

    Penny J. Sinner MPH (Senior Statistician)

Authors
  1. Andrew S. Fink MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. June A. Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Ross McBride MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Micheal J. Hervey II MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Penny J. Sinner MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jodi L. Mammenga BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guy R. Sherwood DABR
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lori Copsey CMD, BS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Research, Education and Clinical Excellence, Baylor University Medical Center, 1201 Barnett Tower 3600 Gaston Avenue, Dallas, TX, 75246, USA

    Harold C. Urschel Jr. MD (Chair of Cardiovascular and Thoracic Surgical) (Chair of Cardiovascular and Thoracic Surgical)

  2. Arizona Oncology Services at St. Joseph’s Hospital & Medical Center Department of Radiation Oncology CyberKnife Center Barrow Neurological Institute, Gamma Knife Center, 350 West Thomas Road, Phoenix, Arizona, 85013, USA

    John J. Kresl MD, PhD

  3. The Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, PUH, C-800, 200 Lothrop Street, Pittsburgh, PA, 15213, USA

    James D. Luketich MD (Sampson Family Endowed Professor of Surgery Chief) (Sampson Family Endowed Professor of Surgery Chief)

  4. Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5801 Forest Park Road, Dallas, TX, 75390, USA

    Lech Papiez PhD (Associate Professor) & Robert D. Timmerman MD (Professor and Vice-Chairman Effie Marie Cain Distinguished Chair in Cancer Therapy Research) (Associate Professor) &  (Professor and Vice-Chairman Effie Marie Cain Distinguished Chair in Cancer Therapy Research)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fink, A.S. et al. (2007). Toxicity and Efficacy of Treating Mediastinal and Hilar Lesions. In: Urschel, H.C., Kresl, J.J., Luketich, J.D., Papiez, L., Timmerman, R.D., Schulz, R.A. (eds) Treating Tumors that Move with Respiration. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69886-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-69886-9_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-69885-2

  • Online ISBN: 978-3-540-69886-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation